D. Callow

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.

J. Weber, B. Peters, G. Patou, 1997, The Journal of infection.

Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to env epitopes and relationship to neutralization.

P. Kaleebu, S. Beddows, S. Shaunak, 1992, The Journal of infectious diseases.

Immunization of human HIV‐seronegative volunteers with recombinant p17/p24: Ty virus‐like particles elicits HIV‐1 p24‐specific cellular and humoral immune responses

Seamus J. Martin, A. Kingsman, J. Senior, 1993, AIDS.

Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers.

A. Kingsman, J. Weber, S. Adams, 1995, Vaccine.

Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. WHO Network for HIV Isolation and Characterization.

P. Kaleebu, J. Weber, S. Beddows, 1994, AIDS research and human retroviruses.

Adaptation of Staphylococcus Aureus to Growth in the Presence of Certain Antibiotics

E. Abraham, K. Gilliver, D. Callow, 1946, Nature.

Identification of human immunodeficiency virus type 1 subtypes and their distribution in the Commonwealth of Independent States (Former Soviet Union) by serologic V3 peptide-binding assays and V3 sequence analysis.

P. Kaleebu, J. Weber, A. Bobkov, 1993, The Journal of infectious diseases.

Comparative humoral responses to HIV-1 p24gag and gp120env in subjects from East Africa and the UK.

P. Kaleebu, E. Katabira, R. Brindle, 1991, AIDS.